The Associated Press @AP
Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for Lou Gehrig’s disease, even as they prepare to give its drugmaker a rare second opportunity to make a public case for the treatment. https://t.co/D7CkmcubTA — PolitiTweet.org